



17 July 2017

Board Appointment

It is with great pleasure that Optiscan announces the appointment of Philip Currie to the board, as a Non-Executive Director, with immediate effect.

Process Background

Optiscan is now at an exciting time in the life of the company. As we move ever closer to the delivery of our Zeiss collaboration project on the world stage, our strategic focus shifts from one of development to one of delivery.

Pivotal to that is the acceptance of our product in the medical space and the future development of our product into additional fields. This was outlined in our June Market Update under the heading "Exploring new market opportunities for related Optiscan products and services".

In keeping with this new phase of the lifespan of Optiscan, the board has recently undertaken a performance review to ensure that it is relevant to the current and future direction - and has the skillsets required for the future expansion of the business.

The review identified a gap in the clinical knowledge space on the board resulting in the need for a board member with strong credentials in the medical field.

Director Background

Dr Philip Currie MBBS (Hons), FRACP, MBA

Philip Currie is a cardiologist with more than 35 years in cardiology both in the United States and in Australia with extensive experience in medical research, clinical cardiology and business. He has a medical degree, MBBS (Hons) from Monash University and an MBA from the University of Michigan.

He completed his medical residency and cardiology fellowship at the Alfred Hospital in Melbourne before moving to the USA in 1983. At the Mayo Clinic, he completed a cardiology fellowship and then was a Senior Associate Cardiologist. He then was a staff cardiologist for 3 years at the Cleveland Clinic and then to Michigan as the Director of Echocardiography at the Michigan Heart and Vascular Institute for 8 years. During his time in the USA, Philip was involved in the research/pioneering/validation of many of the major advances in echocardiography (including Doppler echo, intraoperative echocardiography and transoesophageal echocardiography) including working closely as a luminary with the major international ultrasound manufacturers.

In 1997, after working in the USA for 14 years, Philip returned to Australia and over the last 20 years he has successfully established a private cardiology practice which has subsequently evolved to become an integrated multispecialty medical organisation with 12 sites in Perth and Melbourne.

Phone (61 3) 9538 3333

Website www.optiscan.com

PO Box 1066, Mt Waverley MDC VIC 3149 Australia

Closing Remarks

Philip Currie brings to the board a wide range of skills and broad experience including medical knowledge, medical research background, experience as the luminary interacting with international ultrasound companies, and extensive business skills based on previous MBA and a 20 year experience as the founder, owner and CEO of a large integrated medical organisation.

Optiscan is delighted to have someone of Phil Currie's obvious knowledge, skills and background on the board of the company.

His appointment adds an increased breadth of knowledge to an already strong board bolstering the knowledge base as Optiscan moves from a position as a local developer to a global player in the field of confocal microscopy.

For further information:

Alan Hoffman
Chairman
Em: ahoffman@optiscan.com

About Optiscan

Optiscan is an Australian company that has developed and patented miniaturised confocal microscopes, and is a global leader in the development and application of microscopic imaging and related technologies for medical and research markets.

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan, are forward-looking statements. Forward-looking statements can be identified by words such as 'anticipate', 'believe', 'could', 'estimate', 'expect', 'future', 'intend', 'may', 'opportunity', 'plan', 'potential', 'project', 'seek', 'will' and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.